Researchers evaluated a drug that represents a new class of anticoagulants known as Factor XI inhibitors for treating patients with atrial fibrillation as part of the AZALEA-TIMI 71 Study. The trial ...

Clinically significant reductions in bleeding underscore abelacimab’s strong potential to address an unmet need for patients ...

Abelacimab, a factor XI inhibitor, demonstrated a 62–69% reduction in major bleeding compared to rivaroxaban in atrial fibrillation patients at moderate-to-high stroke risk, with comparable safety and ...

That's significant because the GI tract is the most common site of bleeding with DOACs, and this type of bleeding is the only one for which DOACs do not have a better risk profile ...

One of the most commonly used types of medication to prevent strokes is blood thinners. These medications reduce the risk of ...

Saint Francis treated its first patient with pulsed-field ablation, which delivers pulsed electric fields to tissue to treat ...

A New Pacemaker Algorithm for the Treatment of Atrial Fibrillation: Results of the Atrial Dynamic Overdrive Pacing Trial (ADOPT) Electrophysiologic Characteristics of the Spontaneous Onset and ...